{
    "clinical_study": {
        "@rank": "151397", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1:CY/GVAX concurrently with SGI-110", 
                "arm_group_type": "Experimental", 
                "description": "During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2, the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells, and SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin."
            }, 
            {
                "arm_group_label": "Cohort 2: CY/GVAX after SGI-110", 
                "arm_group_type": "Experimental", 
                "description": "During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2, Cyclophosphamide (CY) is administered on Day 8 at 200 mg/m2, and the colon cancer tumor vaccine (GVAX) is administered on Day 9 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin."
            }, 
            {
                "arm_group_label": "Cohort 3: CY/GVAX", 
                "arm_group_type": "Experimental", 
                "description": "During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 and the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin."
            }, 
            {
                "arm_group_label": "Cohort 4: SGI-110", 
                "arm_group_type": "Experimental", 
                "description": "During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will be looking at whether CY/GVAX in combination with SGI-110 is effective\n      (recruits CD45RO+ T cells to the tumor which may be a marker of anti-tumor activity) and\n      safe in patients with metastatic colon or rectum cancers."
        }, 
        "brief_title": "SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)", 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Colonic Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Documented cancer of the colon or rectum who have received and are stable on first or\n             second-line therapy regimens for metastatic colorectal cancer\n\n          2. ECOG Performance Status of 0 to 1\n\n          3. Adequate organ function as defined by study-specified laboratory tests\n\n          4. Must use acceptable form of birth control through the study and for 28 days after\n             final dose of study drug\n\n          5. Signed informed consent form\n\n          6. Willing and able to comply with study procedures\n\n        Exclusion Criteria:\n\n          1. Currently have or have history of certain study-specified heart, liver, kidney, lung,\n             neurological, immune or other medical conditions\n\n          2. Systemically active steroid use\n\n          3. Another investigational product within 28 days prior to receiving study drug\n\n          4. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring\n             within 28 days prior to receiving study drug\n\n          5. Chemotherapy, radiation, hormonal, or biological cancer therapy within 28 days prior\n             to receiving study drug\n\n          6. Pregnant or lactating\n\n          7. Unwilling or unable to comply with study procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01966289", 
            "org_study_id": "J13138", 
            "secondary_id": "NA_00087578"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1:CY/GVAX concurrently with SGI-110", 
                    "Cohort 2: CY/GVAX after SGI-110", 
                    "Cohort 3: CY/GVAX"
                ], 
                "description": "CY is administered intravenously at 200 mg/m2", 
                "intervention_name": "CY", 
                "intervention_type": "Drug", 
                "other_name": "Cyclophosphamide, Cytoxan"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1:CY/GVAX concurrently with SGI-110", 
                    "Cohort 2: CY/GVAX after SGI-110", 
                    "Cohort 3: CY/GVAX"
                ], 
                "description": "GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells", 
                "intervention_name": "GVAX", 
                "intervention_type": "Biological", 
                "other_name": "Colon cancer tumor vaccine"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1:CY/GVAX concurrently with SGI-110", 
                    "Cohort 2: CY/GVAX after SGI-110", 
                    "Cohort 4: SGI-110"
                ], 
                "description": "SGI-110 is administered subcutaneously at 60 mg/m2", 
                "intervention_name": "SGI-110", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cyclophosphamide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Colorectal Neoplasms", 
            "Intestinal Neoplasms", 
            "Gastrointestinal Neoplasms", 
            "Digestive System Neoplasms", 
            "Neoplasms by Site", 
            "Neoplasms", 
            "Digestive System Diseases", 
            "Gastrointestinal Diseases", 
            "Colonic Diseases", 
            "Intestinal Diseases", 
            "Rectal Diseases"
        ], 
        "lastchanged_date": "October 16, 2013", 
        "location": {
            "contact": {
                "email": "judkica@jhmi.edu", 
                "last_name": "Carol Judkins, RN", 
                "phone": "410-614-5241"
            }, 
            "contact_backup": {
                "email": "nazad2@jhmi.edu", 
                "last_name": "Nilofer Azad, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21231"
                }, 
                "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Pilot Study of SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) as Maintenance Therapy", 
        "overall_contact": {
            "email": "judkica@jhmi.edu", 
            "last_name": "Carol Judkins, RN", 
            "phone": "410-614-5241"
        }, 
        "overall_contact_backup": {
            "email": "nazad2@jhmi.edu", 
            "last_name": "Nilofer Azad, MD"
        }, 
        "overall_official": {
            "affiliation": "The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", 
            "last_name": "Nilofer Azad, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Difference in CD45RO+ tumor infiltrating lymphocytes (TILs) measured by immunohistochemistry in pre and post-treatment tumor biopsies from patients with  metastatic colorectal cancer", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01966289"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Time To Progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }
        ], 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}